Outlook: Glaxo Wellcome
THE DECISIVE manner in which Sir John is building his oil empire contrasts starkly with the series of abortive merger attempts made by Glaxo Wellcome's Sir Richard Sykes. First he failed to tie the knot with SmithKline Beecham after falling out with Jan Leschley on the way up the aisle. Now his overtures to an an American bride, Bristol Myers Squibb, have come to nought.
There again, perhaps the dalliance with the Americans was merely designed to lure SmithKline Beecham back to the negotiating table. As every lover knows, there is nothing like jealousy to spice up a flagging relationship. If nothing else, we may at last discover if Mr Leschly's new-found love for independence is for real or just tactical talk while he bides his time until departing.
Sir Richard's end-game is known. He wants to build Glaxo into the world's largest drug company with 10 per cent of the market as quickly as possible. According to figures released yesterday by the consultancy IMS Health, Glaxo is number three in the world, within spitting distance of the leaders Novartis and Merck.
The UK company could reach the top through organic growth, but to get from the present 4 per cent market share to the magic 10, Sir Richard needs a deal. He, and the City, would like it to be with SKB, but if that doesn't materialise, Sir Richard is prepared to talks to others, as the Bristol Myers Squibb discussions show. Given Glaxo's strong hand, it is time for the other players and particularly SmithKline to end their bluffs and put their cards on the table.
Comments
Share your thoughts and debate the big issues
Please be respectful when making a comment and adhere to our Community Guidelines.
You can find our Community Guidelines in full here.
- -1) ? 'active' : ''">
Newest first
- -1) ? 'active' : ''">
Oldest first
- -1) ? 'active' : ''">
Most liked
{{/moreThanOne}}Please be respectful when making a comment and adhere to our Community Guidelines.
You can find our Community Guidelines in full here.
- -1) ? 'active' : ''">
Newest first
- -1) ? 'active' : ''">
Oldest first
- -1) ? 'active' : ''">
Most liked
{{/moreThanOne_p}}Follow comments
Vote
Report Comment
Subscribe to Independent Premium to debate the big issues
Want to discuss real-world problems, be involved in the most engaging discussions and hear from the journalists? Start your Independent Premium subscription today.
Already registered? Log inReport Comment
Delete Comment
About The Independent commenting
Independent Premium Comments can be posted by members of our membership scheme, Independent Premium. It allows our most engaged readers to debate the big issues, share their own experiences, discuss real-world solutions, and more. Our journalists will try to respond by joining the threads when they can to create a true meeting of independent Premium. The most insightful comments on all subjects will be published daily in dedicated articles. You can also choose to be emailed when someone replies to your comment.
The existing Open Comments threads will continue to exist for those who do not subscribe to Independent Premium. Due to the sheer scale of this comment community, we are not able to give each post the same level of attention, but we have preserved this area in the interests of open debate. Please continue to respect all commenters and create constructive debates.